By David Fairfield, Senior Vice President, Feed, for the National Grain and Feed Association (NGFA)
The U.S. Food and Drug Administration (FDA) announced Feb. 4 that it will resume conducting domestic surveillance inspections beginning on Feb. 7 across all types of commodities — human and animal foods, drugs, medical products, and tobacco — given the decline in COVID-19 cases across the country.
In addition to resuming domestic surveillance inspections, FDA will continue to conduct both foreign and domestic mission-critical inspections and proceed with previously planned foreign surveillance inspections that have received country clearance and are within the Center for Disease Control and Prevention’s (CDC) Level 1 or Level 2 COVID-19 travel recommendation.
Planning for additional foreign surveillance inspections is ongoing, with an anticipated goal of conducting foreign prioritized inspections starting in April.
FDA also is continuing remote foreign supplier verification program activities for human and animal foods.
Additionally, FDA said that state inspections under agency contract have the discretion to make inspection decisions based on their local information.
— From the Feb. 11 NGFA Newsletter